Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1368 ARTÍCULOS , VIENDO DEL 1291 AL 1305

An Overview of Primary Dementias as Clinicopathological Entities

Salardini A.

Semin Neurol. 2019 Apr;39(2):153-166. doi: 10.1055/s-0039-1683445. Epub 2019 Mar 29.

CSF Cytokines in Aging, Multiple Sclerosis, and Dementia

Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WR.

Front Immunol. 2019 Mar 15;10:480. doi: 10.3389/fimmu.2019.00480. eCollection 2019.

Autophagy at synapses in neurodegenerative diseases

Lee W, Kim SH.

Arch Pharm Res. 2019 May;42(5):407-415. doi: 10.1007/s12272-019-01148-7. Epub 2019 Apr 1.

Recent Advances in Apoptosis: THE Role of Hydrazones

Çıkla-Süzgün P, Küçükgüzel ŞG.

Mini Rev Med Chem. 2019;19(17):1427-1442. doi: 10.2174/1389557519666190410125910.

Emerging drugs for progressive supranuclear palsy

Giagkou N, Stamelou M.

Expert Opin Emerg Drugs. 2019 Jun;24(2):83-92. doi: 10.1080/14728214.2019.1609450. Epub 2019 May 20.

Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases

Staff NP, Jones DT, Singer W.

Mayo Clin Proc. 2019 May;94(5):892-905. doi: 10.1016/j.mayocp.2019.01.001.

Long-Term Outcomes of the Benefit-Finding Group Intervention for Alzheimer Family Caregivers: A Cluster-Randomized Double-Blind Controlled Trial

Cheng ST, Chan WC, Lam LCW.

Am J Geriatr Psychiatry. 2019 Sep;27(9):984-994. doi: 10.1016/j.jagp.2019.03.013. Epub 2019 Mar 26.

Modification of the gut microbiome to combat neurodegeneration

Sasmita AO.

Rev Neurosci. 2019 Nov 26;30(8):795-805. doi: 10.1515/revneuro-2019-0005.

Toxoplasma gondii infection and risk of Parkinson and Alzheimer diseases: A systematic review and meta-analysis on observational studies

Bayani M, Riahi SM, Bazrafshan N, Ray Gamble H, Rostami A.

Acta Trop. 2019 Aug;196:165-171. doi: 10.1016/j.actatropica.2019.05.015. Epub 2019 May 15.

Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases

Nishibori M, Mori S, Takahashi HK.

J Pharmacol Sci. 2019 May;140(1):94-101. doi: 10.1016/j.jphs.2019.04.006. Epub 2019 May 4.

α-synuclein in the pathophysiology of Alzheimer's disease

Twohig D, Nielsen HM.

Mol Neurodegener. 2019 Jun 11;14(1):23. doi: 10.1186/s13024-019-0320-x.

Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease

Dunn AR, O'Connell KMS, Kaczorowski CC.

Neurosci Biobehav Rev. 2019 Aug;103:73-80. doi: 10.1016/j.neubiorev.2019.06.018. Epub 2019 Jun 14.

Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View

Cenini G, Lloret A, Cascella R.

Oxid Med Cell Longev. 2019 May 9;2019:2105607. doi: 10.1155/2019/2105607. eCollection 2019.

miRNAs Identify Shared Pathways in Alzheimer's and Parkinson's Diseases

Sadlon A, Takousis P, Alexopoulos P, Evangelou E, Prokopenko I, Perneczky R.

Trends Mol Med. 2019 Aug;25(8):662-672. doi: 10.1016/j.molmed.2019.05.006. Epub 2019 Jun 17.

Mangiferin: A multipotent natural product preventing neurodegeneration in Alzheimer's and Parkinson's disease models

Feng ST, Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y.

Pharmacol Res. 2019 Aug;146:104336. doi: 10.1016/j.phrs.2019.104336. Epub 2019 Jul 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias